Literature DB >> 22358929

Kinetics of retroviral production from the amphotropic ΨCRIP murine producer cell line.

B Q Shen1, M F Clarke, B O Palsson.   

Abstract

Rapidly expanding development and practice of gene therapy requires the availability of large quantities of high titer retroviral supernatants. One way to achieve high retroviral titers is through improved understanding of the kinetics of retroviral production and decay, and the subsequent development of improved cell culture methods. In the present study we investigated the effects of different operational modes on the retroviral production of the NIH 3T3 fibroblast derived amphotropic murine retroviral producing cell line pMFG/ΨCRIP. Semi-continuous culture (exchange of 50% of medium volume daily) was found to promote cell growth and enhance retroviral production. The rapid medium exchange resulted in significantly larger amounts of high titer supernatants and an extended production phase as compared to the batch control cultures. The specific viral productivity of the pMFG/ΨCRIP cells was in the range of 10 to 40 infectious viruses produced per thousand producer cells per day. The CV-1 African Green Monkey kidney cell line was used as the infection target. Lowering the serum level form 20% to 10% improved retroviral production slightly. However, at lower serum levels (1%, 5% and 10% (v/v)) growth of the producer cell line, and thus retroviral production, was directly proportional to the serum level. The half-life of the virus at 37°C was found to be 5.5 hours. Promoting the growth of producer cell lines can improve retroviral vectors titers and viral production. High cell density systems that allow for rapid cell growth and waste product removal are likely to be used to generate high-titer retroviral supernatants.

Entities:  

Year:  1996        PMID: 22358929     DOI: 10.1007/BF00353938

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  12 in total

Review 1.  Genes in a bottle.

Authors:  M Bluestone
Journal:  Biotechnology (N Y)       Date:  1992-02

2.  Gene therapy.

Authors:  I M Verma
Journal:  Sci Am       Date:  1990-11       Impact factor: 2.142

3.  Mitochondrial protein p26 BCL2 reduces growth factor requirements of NIH3T3 fibroblasts.

Authors:  J C Reed; H S Talwar; M Cuddy; G Baffy; J Williamson; U R Rapp; G J Fisher
Journal:  Exp Cell Res       Date:  1991-08       Impact factor: 3.905

4.  Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobins.

Authors:  H R Sunshine; J Hofrichter; W A Eaton
Journal:  J Mol Biol       Date:  1979-10-09       Impact factor: 5.469

5.  Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges.

Authors:  O Danos; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

6.  Ammonia effects in cultures of normal and transformed 3T3 cells.

Authors:  W J Visek; G M Kolodny; P R Gross
Journal:  J Cell Physiol       Date:  1972-12       Impact factor: 6.384

Review 7.  Retrovirus packaging cells.

Authors:  A D Miller
Journal:  Hum Gene Ther       Date:  1990       Impact factor: 5.695

8.  Natural immunity in mice to structural polypeptides of endogenous type C RNA viruses.

Authors:  J R Stephenson; R L Peters; S Hino; R M Donahoe; L K Long; S A Aaronson; G J Kelloff
Journal:  J Virol       Date:  1976-09       Impact factor: 5.103

9.  Widespread natural occurrence of high titers of neutralizing antibodies to a specific class of endogenous mouse type-C virus.

Authors:  S A Aaronson; J R Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

10.  Position-independent, high-level expression of the human beta-globin gene in transgenic mice.

Authors:  F Grosveld; G B van Assendelft; D R Greaves; G Kollias
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

View more
  7 in total

1.  A High-throughput End-point Assay for Viable Mammalian Cell Estimation.

Authors:  Xianghui Gong; Qiangyi Fang; Xuesen Li; Xiangzong Han; Yuyin Wu; Shengli Yang; Bing Q Shen
Journal:  Cytotechnology       Date:  2005-09       Impact factor: 2.058

2.  Cell culture processes for the production of viral vectors for gene therapy purposes.

Authors:  James N Warnock; Otto-Wilhelm Merten; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2006-06-30       Impact factor: 2.058

3.  Justification of continuous packed-bed reactor for retroviral vector production from amphotropic PsiCRIP murine producer cell.

Authors:  S H Kang; B G Kim; G M Lee
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

4.  Fed-batch culture optimization of a growth-associated hybridoma cell line in chemically defined protein-free media.

Authors:  Xianghui Gong; Dongxiao Li; Xuesen Li; Qiangyi Fang; Xiangzong Han; Yuyin Wu; Shengli Yang; Bing Q Shen
Journal:  Cytotechnology       Date:  2006-12-02       Impact factor: 2.058

5.  Expression of IMP1 enhances production of murine leukemia virus vector by facilitating viral genomic RNA packaging.

Authors:  Yun Mai; Guangxia Gao
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

6.  Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.

Authors:  Xiuyan Wang; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Shirley Bartido; Gregory Hermetet; Michel Sadelain; Isabelle Rivière
Journal:  J Immunother       Date:  2015-04       Impact factor: 4.456

Review 7.  Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.

Authors:  Felipe Tapia; Daniel Vázquez-Ramírez; Yvonne Genzel; Udo Reichl
Journal:  Appl Microbiol Biotechnol       Date:  2016-01-13       Impact factor: 4.813

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.